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Summary 
Movento 100 SC is a new insecticide containing the active substance spirotetramat. The 
intended use is in stone fruit, pome fruit, vegetables and ornamentals outdoors, and lettuce, 
tomatoes and cucumbers in greenhouses.  
VKM was requested by the Norwegian Food Safety Authority to consider possible health risk 
for operators related to the properties of Movento 100 SC; in particular the relevance of the 
effects of spirotetramat on thyroid hormones, brain, thymus and body weight observed in 
dogs, and the reproductive effects of spirotetramat observed in rats. VKM was also asked to 
consider the fate and behaviour of Movento 100 SC with the active ingredient spirotetramat in 
the environment, and the ecotoxicological effects and risks related to its use. The risk 
assessment was finalized in a meeting on May 24. 2013, by VKM’s Scientific Panel on Plant 
Protection Products. 
 
VKM’s conclusions are as follows:   
Health 
VKM concludes that spirotetramat shows toxic effects in dogs and rats that could be relevant 
for humans. Thyroid and thymus glands are target organs in the oral subchronic toxicity 
studies of spirotetramat in dogs, and effects are observed from 19 mg/kg bw/day (600 ppm). 
Decreases in circulating thyroid hormone levels were detected in all three studies carried out 
with dogs (28-, 90-days and 1-year) and should be considered toxicologically relevant. The 
opinion of the Panel is that it cannot be excluded that the observed brain dilatation in dogs is 
treatment-related, and relevant to humans.  
Furthermore, VKM concludes that the reproductive effect observed in rats could be relevant 
for humans. 
VKM proposes a NOAEL of 5 mg/kg bw/day (200 ppm) for spirotetramat based on a 1- year 
toxicity study in dogs, and a NOAEL of 100 mg/kg bw/day based on the acute neurotoxicity 
study in rats.  
VKM supports/proposes: 
• ADI: 0.05 mg/kg bw/day. 
• AOEL: 0.05 mg/kg bw/day. 
• ARfD: 1 mg/kg bw/day. 
Risk calculations show minimal risk if personal protective equipment is used. 
Environment 
VKM concludes that spirotetramat and its metabolites are not expected to accumulate in soil. 
It is not expected that spirotetramat or any of its metabolites will reach concentrations in 
groundwater above the threshold level of 0.1 μg/L when the formulation Movento 100 SC is 
applied according to the intended use. 
VKM concludes that use of Movento 100 SC with the active substance spirotetramat 
according to the proposed application scheme in Norway represents a minimal risk of adverse 
effects on terrestrial mammals, birds, earthworms, and soil microorganisms. However, in-
field effects on sensitive species of predatory mites in the crop cannot be excluded. 
The risk of adverse effects on bees is minimal providing that spirotetramat is not used on 
crops during flowering or when bees are actively foraging. 
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For aquatic organisms in surface water, the risk is considered minimal, provided that a 5 m 
buffer zone to open water is used. 
 
Background 
VKM performs risk assessments in the context of pesticide registration, cf. Regulation on 
Pesticides § 4. The Norwegian Food Safety Authority, National Registration Section, is 
responsible for reviewing and evaluating the documentation submitted by the pesticide 
notifier. The Norwegian Food Safety Authority takes the final regulatory action regarding 
registration or deregistration of pesticides based on VKMs risk assessment, along with a 
comparative assessment of risk and benefits, and the availability of alternatives (the principle 
of substitution).  
The Norwegian Food Safety Authority submitted a request on April 18, 2013 for VKM to 
perform a risk assessment on use of the pesticide Movento 100 SC containing the active 
substance spirotetramat. The risk assessment was finalized in June, 2013. 
 
Terms of reference 
Movento 100 SC is a new product containing the new active substance spirotetramat. The 
intended use is as an insecticide in stone fruit, pome fruit, vegetables and ornamentals 
outdoors, and lettuce, tomatoes and cucumbers in greenhouses.  
In this regard, The Norwegian Food Safety Authority would like an assessment of the 
following: 
• The human health risk for operators related to the properties of Movento 100 SC and 
spirotetramat. The Panel is in particular asked to look at the following:  
o The human health relevance of the observed effects of spirotetramat on thyroid 
hormones, brain, thymus and body weight observed in dogs. 
o The human health relevance of the reproductive effects of spirotetramat 
observed in rats. 
• The fate and behaviour in the environment and the ecotoxicological effects and risks 
with regard to the properties of Movento 100 SC and spirotetramat. 
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1 Background documentation 
VKM’s risk assessment is based on the Norwegian Food Safety Authority’s evaluation of the 
documentation submitted by the applicant. The Norwegian Food Safety Authority publishes 
both their evaluation of Movento 100 SC and their final regulatory action on the registration 
of the pesticide product at their homepage www.Mattilsynet.no. 
 
2 Procedure 
The first three steps of the risk assessment (hazard identification, hazard characterization and 
assessment of exposure) are performed by the Norwegian Food Safety Authority and involve 
an assessment of the documentation submitted by the pesticide notifier. The resulting report 
on hazard identification, hazard characterization and assessment of exposure, from which the 
summary is included in the present document, is then reviewed by VKM. This review may 
result in some amendments in the original documents of both the summary and the full report 
issued by the Norwegian Food Safety Authority. The fourth step (risk characterization) is 
based on the three first steps and is VKM’s conclusions or risk assessment.  
 
2.1 HEALTH RISK ASSESSMENT 
The assessment of health risk of pesticides is based on the adverse effects produced by the 
active substance and product in several experimental test systems including long term animal 
studies. On the basis of this, limits of exposure which represent no health risk are determined. 
The limits take into account the uncertainties of extrapolating data from animals to humans 
and are compared to the operator exposure and human exposure to possible residues in food.  
The UKPoem and the German model are used to estimate operator exposure. The models are 
based on a limited number of studies and are not validated. Thus, the models may not always 
be sufficiently representative for Norwegian conditions. The limitations of model estimates of 
exposure are taken into consideration when the calculated level of exposure is close to the 
threshold limit for acceptable operator exposure (Acceptable Operator Exposure Level; 
AOEL). VKM uses the 75 percentile of exposure assessment for both UK poem and German 
model. VKM has to base the assessment on the models whenever exposure data for the 
product is not present.  
VKM makes use of a higher safety factor when calculating AOEL and ADI in cases where the 
product contains critical active substances with serious adverse inherent properties (toxic to 
reproduction or carcinogenic). 
In order to describe the exceeding of maximum tolerated dose, VKM makes use of a scale. 
The scale is based on the ratio between the estimated exposure based on models or measured 
exposure in field studies and the Acceptable Operator Exposure Level (AOEL). In cases 
where the estimated exposure significantly exceeds AOEL, the use of the products may lead 
to increased risk for health effects.  
 
The following scale is used: 
Very high excess of AOEL more than 500% of the limit   
High excess of AOEL  300 – 500% of the limit  
Medium excess of AOEL 150-300% of the limit  
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Moderate excess of AOEL  100-150% of the limit    
The limit is not exceeded 
 
VKM may also consider co-formulants in the product when risk is to be determined. 
Consequently, if a product contains critical co-formulants it may be assessed to represent 
higher risk than what the inherent properties of active substances imply.   
 
 
2.2 ENVIRONMENTAL RISK ASSESSMENT 
The environmental risk assessment of pesticides involves predictions of exposure 
concentrations in various environmental compartments (e.g. soil and surface waters) that may 
occur after application of the pesticide. These predicted effect concentrations (PECs) are 
compared to exposure levels that are known to cause toxic effects to important groups of 
organisms representing the environmental compartments.  
The environmental fate and possible ecotoxicological effects of pesticides are investigated in 
several laboratory- and field experiments. In environmental risk assessments of pesticides, 
Predicted Environmental Concentrations (PECs) are estimated by use of different scenarios 
for different parts of the environment (terrestrial, aquatic). The first parameter estimated is 
usually the initial concentration (PIEC, Predicted Initial Environmental Concentration), e.g. 
the concentration just after application (usually spraying). PIEC in soil is calculated assuming 
a homogenous distribution of areal dose in the upper 5 cm soil layer. For surface water, the 
PIEC is based on deposition of pesticides from spray drift in a standard size water body. The 
calculations are performed with application of buffer zones between the sprayed area and the 
water body. 
The further exposure regime in different compartments is affected on the fate of the pesticide. 
The fate is dependent on processes such as photo degradation, hydrolysis, biodegradation and 
sorption to soil particles. These processes are studied in several standardised laboratory tests. 
In addition, field tests are used to study the dissipation of the pesticide in various agricultural 
soils. Based on the experimental fate studies, factors describing different fate processes may 
be derived and used in models that describe the fate of the pesticide in the soil as well as the 
transport to surface water and ground water. The concentrations of the pesticide in water are 
estimated by use of models with relevant scenarios based on EU’s FOCUS-scenarios. The 
models produce maximum PEC and average PEC calculated for specified periods after 
pesticide application. In the surface water scenarios PEC is also calculated for the sediment 
phase. 
Then the Toxicity Exposure Ratio (TER) is estimated for different groups of organisms. The 
TER is calculated as the ratio between the toxicity for the organism in question (expressed as 
LC50, EC50, NOEC etc., depending on organism and study type) and PEC or PIEC. Trigger 
values for TER, which express the acceptability of the risk for different organisms, have been 
defined by the EU. The risk is considered minimal when the TER does not exceed the trigger 
value.  
In the terrestrial environment, the risk for toxic effects on bees and non-target arthropods is 
assessed according to other criteria. Hazard quotients for oral- (HQO) and contact toxicity 
(HQC) are estimated for bees. HQO or HQC is the ratio between the standardized area dose of 
the product (g a.s./ha) and acute toxicity for the bee (LD50, µg active ingredient/bee). Field 
experiments and expert evaluation is triggered whenever the hazard quotient is above 50.  
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For the non-target arthropods, the estimated hazard quotient (HQ) is the ratio between the 
area dose of the product (g active ingredient/ha), which is multiplied with a factor for multiple 
applications (MAF, multiple application factor) when appropriate, and the acute toxicity for 
the organism (LR50, g active ingredient/ha). According to EU, whenever the ratio value 
exceeds 2, further investigations are triggered.  
VKM makes use of a scale in order to describe the risk of exposure for different organisms 
which live within and outside the spraying field. The scale is based on the ratio between the 
estimated exposure and the limit or the ratio between the TER and the TER trigger value 
designated each group of organism.  
The following risk scale is used:  
Very high risk  more than 500% of the limit   
High risk  300 – 500% of the limit  
Medium risk   150-300% of the limit  
Moderate risk  110-150% of the limit 
Minimal risk   the limit is not exceeded 
The estimates of exposure concentrations are based on maximal concentrations, which exist 
during or shortly after spraying. The group of organism assessed (for example birds or leaf 
dwelling non-target organisms) is not always present during the period of maximal 
concentration. In the final risk assessment, VKM therefore takes into consideration whether, 
or to which extent, the organism in question actually will be exposed. This may cause that the 
risk is assessed lower than indicated by the scale above.  
Additionally, uncertainties in the data base both with regard to establishments of limits and 
models of exposure concentrations are taken into consideration if relevant. This may also 
cause that the risk is assessed lower or higher than the risk scale. Any deviation from the risk 
scale is justified in this document.  
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3 Summary by the Norwegian Food Safety Authority 
(hazard identification, hazard characterization and 
assessment of exposure) 
 
Movento 100 SC is a new product containing the new active substance spirotetramat. 
Movento 100 SC is an aqueous suspension concentrate (SC) containing 100 g/L of the active 
substance. The application is for use against biting and sucking insects in apple, pear, plum, 
cherries, white-, red-, savoy- and spring cabbage, Brussels sprouts, cauliflower, broccoli, kale, 
Chinese cabbage, lettuce grown in field and in greenhouse, tomatoes and cucumbers in 
greenhouse and ornamentals outdoors (plant nurseries and urban landscape). 
Movento 100 SC belongs to the main chemical group “Inhibitors of acetyl CoA carboxylase”. 
This is an insecticide with contact and ingestion effect against aphids, scale insects, 
whiteflies, psyllids, gall midges, thrips and mites. The active ingredient spirotetramat 
penetrates the plant tissue (leaves) and is distributed systemically in the xylem and phloem, 
leading to insect death within 2 to 5 days. 
In the enclosed documentation it is noted that Movento 100 SC is gentle against beneficial 
organisms, including biological control agents and bees. Movento 100 SC is classified by 
IOBC as harmless or slightly harmful to beneficial organisms, and could be used in integrated 
pest management (IPM). 
Pome fruit is the largest crop for use of Movento 100 SC, proposed application dose is 2250 
ml Movento 100 SC/ha (225 g spirotetramat/ha), and maximal application number is two per 
season. Based on the product’s use in pome fruit, the standardized area dose is set to 2250 
ml/ha (225 g a.s/ha), corresponding to 225 ml/daa (22,5 g a.s/daa). 
 
3.1  IDENTITY AND PHYSICAL/CHEMICAL DATA 
Product name:  Movento 100 SC 
Active substance:  spirotetramat 
Formulation:   Aqueous suspension concentrate (SC) 
Concentration of 
active substance:  100 g/L 
IUPAC-name:  cis-4-(ethoxycarbonyloxy)-8-methoxy-3-(2,5-xylyl)-1-
azaspiro[4.5]dec-3-en-2-one 
CAS number:   203313-25-1 
 
Structural formula:  
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Molecular weight:  373.45 g/mol 
Solubility in water:  Medium: 29.9 mg/L (20°C, pH 7) 
Vapour pressure:  Low: 5.6 × 10-9 Pa (20°C, purity 99.2%) 
Henrys law constant:  Low: 6.99 × 10-8 Pa m3/mol (20°C, pH 7) 
log Pow:   Medium: 2.51 (20°C, pH 7, purity 99.1%) 
pKa:    10.7 (purity 99.1%) 
 
3.2 MAMMALIAN TOXICOLOGY 
3.2.1 SPIROTETRAMAT 
3.2.1.1  Toxic kinetics  
Absorption: 14C-labelled spirotetramat was readily absorbed after oral administration in all 
three in vivo studies. The absorption rate in rats receiving single doses of 2 or 100 mg/kg bw 
or repeated doses of 2 mg/kg bw for 14 days was between 89 and 98 % of the total recovered 
radioactivity for all dose groups. Peak plasma concentrations (Cmax) were reached within 
0.09 to 2.03 hours (tmax), as calculated using pharmacokinetic modelling.  
Distribution: Radioactivity was fairly equally distributed to blood, organs and tissues with 
preference for liver and kidneys.  
Metabolism: No parent compound was detected in urine, indicating complete metabolism. 
Figure 5.2.1 below shows the proposed metabolic pathway of spirotetramat in rats. The main 
metabolic pathway is cleavage of the ester group resulting in formation of spirotetramat-enol 
as the primary metabolite (53-87 % of dose) from which all other metabolites could be 
derived. The second most prominent metabolite is spirotetramat-desmethyl-enol (5-37 %). 
Other downstream metabolites included spirotetramat-ketohydroxy and spirotetramat–
desmethyl-ketohydroxy and also spirotetramat-enol-GA (glucuronid) and spirotetramat -
enolalcohol. In male rats, the demethylation of spirotetramat-enol to spirotetramat-desmethyl-
enol was higher (25-37 %) as compared to females (5-10 %).  
In the high dose study (1000 mg/kg bw) in male rats, absorption and excretion were slower 
and lower, and radioactivity in plasma was slightly higher than in liver and kidney, as 
compared to the lower-dose tests. This is likely to be caused by saturation of the active 
transport mechanisms. Spirotetramat-enol and spirotetramat-desmethyl-enol were also in this 
test the primary biotransformation products, but spirotetramat-desmethyl-enol occurred at 
lower levels. Saturation of the active transport mechanisms in excretory organs and slow 
depletion and excretion of residues may potentially lead to accumulation in the body 
following repeated high exposure.  
Results of physiologically-based pharmacokinetic (PBPK) modelling (Schmitt, 2006), 
considered adequate by the RMS to describe ADME behaviour of spirotetramat in male rats at 
doses up to 100 mg/kg bw, supports that accumulation could occur due to saturation of the 
renal transport process between doses of 2 to 100 mg/kg bw/day. By running the model it was 
assumed that the compound enters the systemic circulation as spirotetramat-enol and is further 
metabolised to spirotetramat -desmethyl-enol.  
In vitro metabolism was studied in liver beads (immobilised hepatocytes) from male rat, 
mouse and humans, and showed that spirotetramat-enol was the prominent metabolite in all 
species (66-92 %). In mice and humans enol-glucuronide, resulting from the glucuronidation 
of spirotetramat-enol, was the second most prominent metabolite. However, the level of this 
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metabolite was five times higher in mice than in humans (30 % versus 6 %). In rats, no enol-
glucuronide was detected.  
Elimination: Elimination of radioactivity from tissues and organs was almost complete at the 
48-hour termination in both the single and repeated dose groups, indicating that retention and 
accumulation of spirotetramat is unlikely (but may occur at high doses). Spirotetramat was 
excreted rapidly and almost completely within 24 hours, and mainly via urine. Faecal 
excretion accounted for 2-11 %. 
  
3.2.1.2 Acute toxicity 
Spirotetramat is of low acute oral or dermal toxicity and of acute inhalation toxicity (with 
transient signs irritation of upper airways). No classification and labelling are proposed 
regarding acute toxicity.  
Irritation and sensitization: Spirotetramat has potential for eye irritation (rabbits, instillation 
into the conjunctival sac) as well as skin sensitisation (mice, Local Lymph Node Assay). The 
proposed classification is R36 and R43 respectively.  
 
3.2.1.3 Genotoxicity  
Negative results were obtained in five out of six in vitro and both in vivo assays for point 
mutations and chromosomal aberrations with spirotetramat. Spirotetramat was weakly 
positive at cytotoxic concentrations in only one in vitro chromosomal aberration test. Overall, 
the negative findings in the two in vivo chromosomal aberration assays and one unscheduled 
DNA synthesis assay in rat liver cells do not suggest a genotoxic concern for spirotetramat.  
 
3.2.1.4 Sub-chronic toxicity  
The insecticidal mode of action (lipid biosynthesis inhibition) was not reflected in the results 
of the short-term toxicological studies in rodents and dogs. Rats, mice, and dogs did not 
exhibit changes in plasma lipid parameters such as plasma triglycerides and plasma 
cholesterol.  
In rats, the testis was the target organ following sub chronic oral treatment at a high dose. 
Abnormal spermatozoa and hypospermia in the epididymis, decreased testicular weight, and 
testicular degeneration and vacuolization in males were observed in males after 90 days of 
exposure at 10,000 ppm (616 mg/kg bw/day). These effects proved to be reversible in most 
animals after cessation of the treatment. Other effects in sub-chronically treated rats were 
limited to declines in terminal body weight in 10,000 ppm male rats and an increased 
incidence of accumulation of alveolar macrophages in both sexes at 10,000 ppm. Sub-chronic 
exposure of rats by the dermal route yielded no evidence of systemic toxicity when 
spirotetramat was tested up to 1000 mg/kg bw/day. This result may in part reflect the low 
dermal absorption (approximately 10%) in rats.  
In dogs, the thyroid and thymus glands were target organs in oral sub-chronic toxicity studies. 
Sub-chronic exposure of spirotetramat to dogs was characterized by declines in circulating 
thyroid hormones. Despite a lack of correlative changes observed in thyroid weight, thyroid 
histopathology, or thyroid stimulating hormone, these declines are considered to be of 
toxicological relevance. The decline in circulating thyroid hormones may be considered as 
early events in the development of hypothyroidism which may be clinically manifested after 
exposures of longer durations. With respect to the brain dilation observed in the 1-year study 
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with dogs, Bayer Crop Science (BCS) has issued a position paper arguing that brain ventricle 
dilation has been observed in other BCS dog studies and is of hereditary origin and not 
treatment-related. This is also the evaluation of the USEPA. According to information in the 
addendum to the DAR, the observed brain dilatation is also considered as an equivocal effect 
by the RMS. However, when this was discussed at an EU peer review expert meeting on 
spirotetramat, it was concluded that, based on the concurrent control and historical control 
data, it cannot be excluded that it is treatment-related.  
Notably, the thyroid and thymus were unaffected in rats at any dose, while testicular 
histopathology was not observed in dogs.  
In mice, no adverse effects of any kind were observed upon testing spirotetramat orally up to 
the limit dose (7000 ppm).  
Notable, in vitro results from a comparative metabolism study using hepatocytes from male 
rats, mice, and humans revealed species differences in the metabolism of spirotetramat. 
Specifically, mouse hepatocytes were better able than rat or human liver cells to metabolize 
spirotetramat-enol via glucuronidation. Potentially lower levels of the enol metabolite in mice 
in vivo may account for the lack of testicular toxicity observed in this species. However, it 
cannot be excluded that testicular toxicity would occur in humans, who seem to have a 
significantly lower rate of glucuronidation than mice.  
 
3.2.1.5 Chronic toxicity and carcinogenicity  
Chronic toxicity/carcinogenicity studies in rats following dietary exposure to spirotetramat for 
1 and 2 years, and in mice following dietary exposure to spirotetramat for 18 months, did not 
reveal any treatment-related increase in tumour incidence in either sex.  
In rats, target organs were kidney at medium and high doses in both sexes, and liver in 
females exposed to the high dose. Increased incidence of accumulation of alveolar 
macrophages was observed in both rat studies at medium and high dose males and high dose 
females. Other effects included abnormal spermatozoa or increased incidence of exfoliated 
germ cells in high dose male rats in both rat studies, although only statistically significant in 
the 2 year study.  
A Functional Observational Battery assessment (motor activity, grip strength, and sensory 
reactivity to stimuli of different types including e.g., visual, auditory, and proprioceptive 
stimuli) on 10 rats/sex/dose conducted during the last month of the 1 year chronic study did 
not provide any indication of treatment-related neurological effects.  
In mice, no adverse findings were observed up to the limit dose following long-term treatment 
with spirotetramat.  
 
3.2.1.6 Reproductive and developmental toxicity  
Reproductive toxicity and developmental toxicity of spirotetramat was investigated in a two 
generation study and a one generation range-finding study in rats, and in developmental 
studies in rat and rabbit. In addition, a supplementary developmental study in rats was 
performed to clarify the results of the main study.  
Results of the 2-generation reproductive toxicity study in rats provided evidence of male 
reproductive toxicity with abnormal sperm cell morphology and effects on reproductive 
performance, resulting in no pregnancies at high dose. These findings were supported by 
results of a 1- generation range-finding study. Renal toxicity was observed in the F1-adults in 
12 
 
 Norwegian Scientific Committee for Food Safety (VKM)                                                             13-203 
 
the 2-, but not the 1-generation study and offspring toxicity was observed to be limited to 
reduced body weights.  
The applicant (BCS) has issued a position paper on "High dose reproductive effects in male 
rats and their relevance to humans" (Temerowski, 2008). In this paper, BCS argues that 
spirotetramat is not considered to represent a reproductive hazard to humans at the expected 
low dose exposure scenarios routinely generated through the agricultural use of the chemical, 
or even at very high dose accidental exposure. According to BCS, the testicular toxicity 
observed in the 2-generation rat study is not relevant for humans, as humans have the ability 
to conjugate spirotetramat-enol and therefore are expected to be less sensitive than rats to 
effects of spirotetramat on the male reproductive system. Results of the comparative in vitro 
toxicokinetic study, do indeed suggest that humans are able to conjugate spirotetramat-enol. 
However, this conjugation occurred to a five-times lesser extent than in mice where no 
reproductive toxicity was observed. To what extent a low level of this conjugation protects 
against reproductive effects induced by spirotetramat has not been established, and it can 
therefore not be concluded that testicular toxicity only occurs in species unable to conjugate 
spirotetramat-enol (rats). Furthermore, as pointed out by the RMS, it cannot be excluded that 
other metabolites can cause effects similar to those induced by spirotetramat – enol. In 
accordance with the RMS and conclusions made at an EU peer review expert meeting, it is 
therefore suggested that spirotetramat is classified as category 3 reproductive substance with 
R62 (Possible risk of impaired fertility).  
In the developmental toxicity study in rats (Klaus 2004), offspring toxicity was observed at 
maternal toxicity level. In addition, increased incidences of skeletal malformations and 
deviations were observed at the mid and high dose. Equivocal retarded ossification was 
further investigated in a supplementary study and was not considered treatment related. The 
developmental NOAEL was set at 140 mg/kg bw/day. In accordance with the RMS and 
conclusions made at an EU peer review expert meeting, it is based on the increased incidences 
of skeletal malformations and skeletal deviations in rats at maternally toxic levels, suggested 
that spirotetramat is classified as category 3 reproductive substance with R63 (Possible risk of 
harm to the unborn child).  
The developmental study in rabbit did not reveal evidence of primary embryotoxic or 
teratogenic potential of spirotetramat. Developmental variation and malformations were not 
considered treatment related and a developmental NOAEL of 160 mg/kg bw/day was 
suggested by the reviewer. With respect to the rabbit study, it was at the EU peer review 
expert meeting on spirotetramat agreed upon that the maternal NOAEL is 10 mg/kg bw per 
day and the developmental NOAEL is 160 mg/kg bw per day. It was also concluded that 
based on the available data it could not be decided whether the observed abortions (at 40 and 
160 mg/kg bw/d) were due to maternal or developmental toxicity.  
Two mechanistic studies to further investigate the onset of testicular toxicity in rat and the 
testicular toxicity of the metabolite spirotetramat-enol were carried out. The results revealed 
that repeated dosing is necessary to produce male reproductive effects. Based on the results of 
the study in rats treated with the enol-metabolite, it was concluded that reproductive toxicity 
is caused by either the parent compound or the enol-metabolite following enzymatic cleavage.  
 
 
3.2.1.7 Neurotoxicity  
Neurotoxicity of spirotetramat was investigated in one acute neurotoxicity study in rat. No 
data was available on subchronic (rat 90-day) and postnatal developmental neurotoxicity. 
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Clinical signs of toxicity and/or decreased motor activity were observed following a single 
dose of 200 mg/kg bw spirotetramat to rats. These effects were observed with greater severity 
at doses higher than 200 mg/kg bw in this study, as well as in a follow-up study in rats.  
In the larger database, following one-year administration of spirotetramat to dogs, brain 
dilation with dose-related severity was observed in males at ≥ 600 ppm (20 mg/kg bw/day), 
while axonal degeneration in the hypothalamus was observed in one female at 1800 ppm (48 
mg/kg bw/day). Clinical signs of neurotoxicity (dehydration, swelling, decreased activity and 
reactivity, seizures and ataxia) were also observed in one male with brain dilation at the 
highest dose tested. Similar effects were not observed in either rats or mice.  
 
3.2.1.8 Reference values  
ADI: An acceptable daily intake (ADI) of 0.05 mg/kg bw/day is suggested, based on the 
NOAEL of 5 mg/kg bw/day obtained in the one-year oral toxicity study in the dog and an 
uncertainty factor of 100.  
AOEL: An acceptable operator exposure level (AOEL) of 0.05 mg/kg bw/day is suggested, 
based on the NOAEL of 5 mg/kg bw/day obtained in the one-year oral toxicity study in the 
dog and an uncertainty factor of 100  
ARfD: An acute reference dose (ARfD) of 1 mg/kg bw is suggested, based on the NOAEL of 
100 mg/kg bw obtained in the acute neurotoxicity study in the rat and applying an uncertainty 
factor of 100  
3.2.1.9 Co-formulants  
The product, Movento SC 100 / Spirotetramat SC 100 (100 g/l), contains 0.08 % of the 
preservative Preventol D7 (CAS no. 55965-84-9) and 0.12 % of the preservative Proxel GXL 
20% (CAS no. 2634-33-5) and meets the criteria for the following risk classifications: H315, 
H317, H319.  
 
3.2.2 MOVENTO SC 100  
3.2.2.1 Acute toxicity  
Acute toxicity studies on Movento SC 100 were performed with spirotetramat SC 100 G, 
which according to the bridging statement submitted by the applicant does not significantly 
differ from Movento SC 100. The formulation of Spirotetramat SC 100 G was non-toxic after 
acute oral and dermal administration, and induced very low inhalation toxicity (transient 
ungroomed hair coat in both males and females and accelerated breathing in females) to rats 
after nose-only administration. Hence, no classification for acute oral, dermal and inhalation 
toxicity is required.  
 
3.2.2.2 Irritation and sensitization  
Irritation and sensitisation studies on Movento SC 100 were performed with spirotetramat SC 
100 G, which according to the bridging statement submitted by the applicant does not 
significantly differ from Movento SC 100. Spirotetramat SC 100 G was not found to be 
irritating to the eye and skin. However, based on a test conducted with a similar formulation 
expected to exhibit similar effects as Spirotetramat SC 100 G, the formulation is considered 
skin sensitizing and should be classified accordingly (R43 - May cause sensitisation by skin 
contact).  
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3.2.2.3 Dermal absorption  
Dermal absorption of [14C]-Spirotetramat was investigated in one in vivo study with male 
rats using the OD 150 formulation, and in two in vitro studies using human and rat skin, one 
with the OD 150 formulation and one with the SC 240 formulation. Based on these studies 
and discussions at an EU peer review meeting, the following values are proposed for dermal 
absorption of Movento SC 100: 1% and 10 %, for the low and high dilution respectively.  
 
3.2.2.4 Operator exposure  
For the scenarios calculated, the results of the exposure estimations according to the UK 
POEM and the German model and to application in greenhouses do not exceed the proposed 
systemic AOEL of 0.05 mg/kg bw/d, even if no personal protective equipment (PPE) is used, 
with the following exceptions:  
• According to the UKPOEM model (but not the German model) when used without 
any PPE against pest insects in apples grown in field, when applying a tractor-
mounted/trailed broadcast air-assisted sprayer  
• According to both the UKPOEM and German model, when used without any PPE 
against pest insects in apples grown in field, when applying a hand held sprayer.  
 
Notably, no exposure operator exposure estimates exceeded the proposed systemic AOEL of 
spirotetramat of 0.05 mg/kg bw/d when assuming use of gloves during mixing and loading, 
and the use of gloves, coverall and sturdy footwear during application, in line with the skin-
sensitisation potential and proposed R43 classification of spirotetramat.  
 
3.2.2.5 Bystanders and workers exposure  
Estimations of bystander exposure assuming PPE is used is not required since model 
calculations of operator exposures predict the systemic exposure of operators to be well 
within the acceptable exposure levels.  
With respect to workers exposure, the calculated scenarios (tree fruits and ornamental 
assuming arms, body and legs covered, but no use of gloves); the proposed systemic AOEL is 
slightly exceeded for tree fruits (with a worst case assessment of the initial DFR). In line with 
the skin-sensitisation potential and proposed R43 classification of spirotetramat the use of 
gloves are recommended. 
 
3.2.3 RESIDUES IN FOOD OR FEED 
Residues are not discussed in this report. 
 
3.3 ENVIRONMENTAL FATE AND ECOTOXICOLOGICAL EFFECTS 
3.3.1 ENVIRONMENTAL FATE AND BEHAVIOUR 
3.3.1.1 Degradation in soil 
Spirotetramat is rapidly hydrolysed to spirotetramat-enol (max occurrence set to 100% of 
AR). Spirotetramat-enol is oxidised to spirotetramat-ketohydroxy (max occurrence 24% of 
AR), which is hydrolytically opened and transformed into spirotetramat-MA-amide (max 
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occurrence 5.2% of AR). The mineralisation of spirotetramat-MA-amide into CO2 concludes 
this primary pathway. 
The aerobic rate of degradation of spirotetramat is characterised as very high with DT50 
0.10–0.30 days (geometric mean 0.20 days), DT90: 0.34-1.26 days. Spirotetramat-enol also 
degrades very quickly, but with pronounced biphasic kinetics. The DT50 is 0.02-0.18 days 
(geo. mean 0.05 days), DT90: 11-41 days. Spirotetramat-ketohydroxy had a medium to high 
degradation rate with normalised DT50 values ranging from 1.5 to 14 days (geo. mean 4.5 
days), DT90: 5.1-56 days. Degradation of spirotetramat-MA-amide was fast with normalised 
DT50 values ranging from 0.3-4.6 days (geo. mean 1.2 days), DT90 from 1.0-28 days. The 
soil photolysis metabolite 4-methoxy-cyclohexanone degraded very quickly with a DT50 < 1 
day. 
Non-extractable residues (NER) formed in amounts of 22-35 % of applied radioactivity (AR) 
in the spirotetramat study (by 1-3 days) and barely declined after this. In the spirotetramat-
enol study, formation of NER was even more pronounced with NER occurring at 4.2-28 % at 
0 days. The plateau concentration was reached after 1 day, ranging from 40-60 % of AR. 
Until study termination, NER did not decrease significantly. The majority of the NER was 
found in the fulvic acid fraction. 
Mineralisation was relatively high in both the spirotetramat and spirotetramat-enol studies. 
CO2 formation was between 9.7 and 19 % of AR in the spirotetramat degradation study, while 
CO2 formation was even higher in the spirotetramat-enol study, ranging from 17 to 43 % of 
AR. 
The anaerobic primary degradation route is close to identical to the aerobic degradation route. 
Spirotetramat degraded very quickly (DT50 < 1 day). 
Photolysis is not considered an important route of degradation for spirotetramat in soil. 
The field dissipation of unlabelled spirotetramat and its metabolites was studied in four US 
field trials in New York, Florida, California and Washington. These studies were not 
considered relevant for Norwegian conditions. Spirotetramat degraded fast with a dissipation 
half-life of 0.3-1.0 days (geometric mean 0.7 days) and DT90 values 1.1-3.5 days. 
Spirotetramat-enol and spirotetramat-ketohydroxy were the main metabolites. The 
quantification of metabolite residues was compromised by the instability of spirotetramat-enol 
during storage, and no DT50 values for the individual metabolites could be estimated. 
3.3.1.2 Sorption/mobility 
The sorption of spirotetramat can be classified as medium with Kf: 3.70-4.79 L/kg (arithmetic 
mean 4.08 L/kg) and Kfoc: 159-435 L/kg (arithmetic mean 281 L/kg). The sorption of 
spirotetramat-ketohydroxy can be classified as moderate with Kf: 0.51-2.21 L/kg (arithmetic 
mean 1.04 L/kg) and Kfoc: 41.0-99.1 L/kg (arithmetic mean 63.7 L/kg). The sorption of 
spirotetramat-MA-amide can be classified as low with Kf: 0.06-0.18 L/kg (arithmetic mean 
0.11 L/kg) and Kfoc: 4.4-25.5 L/kg (arithmetic mean 9.3 L/kg). The sorption of spirotetramat-
enol had to be studied in a column leaching study. The Koc values derived from the column 
leaching study represents the first and rapidly degrading phase. The sorption can be classified 
as moderate with Koc: 27-99 L/kg (arithmetic mean 55 L/kg) 
3.3.1.3 Degradation in water 
The rate of hydrolysis depended strongly on pH and on temperature. At 25 °C the DT50 
values of spirotetramat were 32.5, 8.6 and 0.32 days at pH 4, 7 and 9, respectively. As 
temperature decreased, degradation rates decreased. The major degradation product was 
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spirotetramat-enol, which was shown to be hydrolytically stable in the same range of 
temperatures and pH. 
Aqueous photolysis can be considered to be an important degradation pathway for 
spirotetramat. In a sterilised buffer solution (pH 5), spirotetramat degraded quickly with a 
half-life of 2.7 days (corresponds to a DT50 of 20.2 days during natural summer light 
conditions). In the dark control DT50 was 26.2 days. In natural water (pH 7.9) the DT50 was 
found to be 0.19 days. In the dark control DT50 was 1.5 days. The major transformation 
products in the natural sterilised water were methoxy-cyclohexyl-aminocarboxylic acid (11.3 
% AR) and methoxy-cyclohexanone (17.5 % AR). The main hydrolysis product 
spirotetramat-enol was also formed. 
Spirotetramat is not readily biodegradable. 
Aerobic water / sediment studies were conducted in two different test systems. For 
spirotetramat, the degradation in the whole system can be classified as very high (DT50 < 1 
day). The maximum amount in sediment was 3.2 % of AR after 1 day. The major metabolites 
were spirotetramat-enol (max 99 % of AR) and spirotetramat-ketohydroxy (max 51% of AR). 
Spirotetramat-enol was shown to degrade slower in aquatic systems than in soil systems, 
degrading at a medium rate (whole system DT50 38 and 59 days). The distribution was max 
79 % of AR in water after 7 days and 37 % of AR in sediment after 60 days. Spirotetramat-
ketohydroxy was stable in both of the studied systems. The distribution after 120 days was 
max 13% of AR in water and 28 % of AR in sediment. The maximum formation of non-
extractable residues (NER) was above 30 % of AR in both systems (max 36 % of AR). The 
mineralisation varied between the systems, but was relatively high, ranging from 5.9 to 24 % 
of AR. 
3.3.1.4 Fate in air 
Calculations using the Atkinson method estimate DT50 in the troposphere of 1.7 hours for 
both spirotetramat and spirotetramat-enol, while a DT50 of 4.3 hours was estimated for 4-
methoxy-cyclohexanone and 2.8 hours for 4-methoxy-cyclohexyl-aminocarboxylic acid 
(assumes 12-hour day and 1.5 × 106 OH- cm-3). Spirotetramat has a vapour pressure of 5.6 × 
10-9 Pa at 20°C, and thus has a low volatility. No significant transfer to the atmosphere is 
expected. 
 
3.3.2 ENVIRONMENTAL EXPOSURE 
3.3.2.1 Soil 
According to a simple model recommended by the EU working group FOCUS the highest 
expected initial concentration (PIEC, predicted initial environmental concentration) in soil 
will be as follows for spirotetramat, spirotetramat-enol, spirotetramat-ketohydroxy and 4-
methoxy-cyclohexanone, respectively: 0.,1, 0.084, 0.032 and 0.003 mg/kg (75 g/ha on bare 
soil in ornamentals returns the highest concentrations). Due to the fast degradation of 
spirotetramat and its metabolites, no accumulation in soil is expected. 
3.3.2.2 Groundwater 
Metabolites considered relevant in groundwater are spirotetramat-enol, spirotetramat-
ketohydroxy, spirotetramat-MA-amide and 4-methoxy-cyclohexanone (the latter from soil 
photolysis). All nine EU FOCUS scenarios were modelled. Results were reported as the 80 
percentile concentration at 1 m depth over 20 years. Concentrations were below 0.001 μg/L 
for all scenarios. Hence, it is not expected that spirotetramat or any of its metabolites will 
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reach concentrations above the threshold level of 0.1 μg/L when the formulation Movento 100 
SC is applied according to the intended use. 
3.3.2.3 Surface water 
Models developed by EU’s working group FOCUS estimate predicted environmental 
concentrations in surface water and sediment for different scenarios. PECsw values have been 
calculated for the use in pome and stone fruit (application 2 x 225 g a.s./ha) and leafy 
vegetables (2 x75 g a.s./ha) up to Step 2 (Northern EU). The highest PEC values resulted 
from the application in pome and stone fruit with PECsw of 11.79, 12.72, 6.33, 1.09 and 0.94 
μg/L for spirotetramat, spirotetramat-enol, spirotetramat-ketohydroxy, 4-methoxy-
cyclohexanone and 4-methoxy-cyclohexyl-aminocarboxylic acid, respectively. The 
corresponding PECsed values were 6.6, 6.35, 3.93, 0.03 and 0.09 μg/kg. Spray drift is 
assumed to be the main route of entry. As no Step 3 calculations were presented, the 
Norwegian Food Safety Authority considered a 5 m drift buffer for spirotetramat. This 
resulted in a PECsw value of 6.3 μg/L. 
 
3.3.3 EFFECTS ON TERRESTRIAL ORGANISMS 
Where there are indications that the plant protection product is more toxic than what can be 
explained by the content of active substance (or studies are conducted only with the product), 
or identified metabolites are more toxic than the active substance, these calculations are 
included in the summary below. If this is not the case, these values and calculations are 
omitted. 
For mammals and birds, the risk assessment is performed according to the EU Guidance 
Document SANCO (2002). The EU triggers (birds and mammals) are >10 and >5 for 
TERacute and TERchronic, respectively. 
3.3.3.1 Mammals 
Low acute toxicity (LD50 > 2000 mg/kg bw/d)- In a rat multigenerational study the 
reproductive NOEC was toxicity 70.7/82.5 mg/kg bw/d (m/f). TER calculations for 
spirotetramat pass the EU triggers based on EU Tier 1 scenarios. 
3.3.3.2 Birds 
Low acute oral toxicity (LD50 > 2000 mg/kg bw/d). NOEC from reproductive studies are 4 
mg/kg bw/d. Spirotetramat passes the EU trigger values for acute exposure (TERacute >600) 
according to the EU screening step with an application rate of 2x225 g a.s./ha in pome fruits. 
TERchronic fails the EU trigger based on tier 1 calculations, but pass the trigger in a higher 
tier risk assessment for the insectivorous indicator species white Wagtail and Blue tit. 
3.3.3.3 Bees 
Spirotetramat shows low contact (LD50 >100 μg/bee) and oral (LD50 >107 μg/bee) toxicity 
to bees. Hazard quotients for contact (Qhc) and oral exposure (Qho) pass the trigger value 
(<50). Because of the potential effects of spirotetramat on brood development (based on the 
effects observed in the semi-field studies and the mode of action of spirotetramat), 
spirotetramat should not be used on crops during flowering or when bees are actively 
foraging. 
3.3.3.4 Non-target arthropods 
Extended laboratory studies on parasitoids and foliage-dwelling predators did not show 
effects above the trigger effect level of 50 %. Effects on predatory mites (T. pyri) however 
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exceeded the ESCORT 2 trigger of 50 % effect (mortality) at doses at and above 42 g/ha. In a 
field study carried out in grape vines no dose-related, statistically significant effects were 
observed during the study period. 
3.3.3.5 Earthworms 
Spirotetramat shows moderate acute toxicity (LC50 > 500 mg/kg d.w. soil). In a chronic 
toxicity study with the predominant soil metabolite spirotetramat-enol the NOEC is 32 mg/kg 
d.w. soil. TER calculations for spirotetramat pass the EU triggers for both acute (≥10) and 
chronic (≥5) toxicity. 
3.3.3.6 Other soil macro organisms 
Low acute toxicity (LD50 > 1000 mg a.s/kg d.w.soil, NOEC 316 mg a.s/kg d.w.soil). TER 
calculations for spirotetramat pass the EU triggers both for acute (≥10) and chronic (≥5) 
toxicity. 
3.3.3.7 Microorganisms 
The effect of technical spirotetramat on N- and C-transformation in soil was studied in 28-
days laboratory tests in accordance with OECD Guideline 216 and 217, respectively. No 
significant effects above the 25% trigger were seen. 
3.3.3.8 Terrestrial plants 
Corn (Zea mays) is the most sensitive species. The intended use of Movento 100 SC in pome 
fruit crops will not constitute an unacceptable risk of adjacent non-target plants provided a 
buffer zone of 3 meters is used. 
3.3.4 AQUATIC ORGANISMS 
Where there are indications that the plant protection product is more toxic than what can be 
explained by the content of the active substances (or studies are only conducted with the 
product), or identified metabolites are more toxic than the active substances, these 
calculations are included in the summary below. If this is not the case, these values and 
calculations are omitted. 
The TER calculations below are based on maximum PEC-values from FOCUS surface water 
modelling and the lowest acute (LC50 or EC50) or chronic (NOEC) values for the different 
organism groups. FOCUS Step 2 is calculated for all tested substances. If the TER fails the 
triggers, PEC values based on drift when applying different buffer zones are calculated. The 
EU triggers for TERacute and TERlong-term are >100 and >10, respectively. PEC and TER 
values for the metabolites of spirotetramat are not included below, since they all show lower 
toxicity than spirotetramat. Movento 100 SC does not seem to be more toxic than can be 
explained by the toxicity of spirotetramat. 
3.3.4.1 Fish 
Spirotetramat is acutely toxic (96h LC50: 1.96-2.59 mg a.s./L), and showed moderate chronic 
toxicity (28d NOEC: 0.534 mg a.s./L) to fish. Spirotetramat-enol and 4-
methoxycyclohexanone showed low acute toxicity (96h LC50: >100 mg/L). Movento 100 SC 
showed moderate acute toxicity (96h LC50: 22.3 mg/L). 
Both acute and long-term TER calculations for spirotetramat pass the EU triggers based on 
Step 2 calculations. 
19 
 
 Norwegian Scientific Committee for Food Safety (VKM)                                                             13-203 
 
3.3.4.2 Invertebrates 
Spirotetramat showed moderate to very high acute toxicity to invertebrates (48h EC50: 0.85- 
>43 mg a.s./L), and low chronic toxicity (21d NOEC: 2.0 mg a.s./L) to Daphnia magna. 
Spiroteramat-enol and 4-methoxycyclohexanone showed low acute toxicity (96h LC50: >100 
mg/L) to D. magna. No studies with Movento 100 SC have been reported. The notifier argues 
that daphnids are less sensitive than fish, algae and sediment-dwelling organisms. 
Acute TER for use in fruit fail the EU trigger based on Step 2 calculations, but pass the 
trigger based on drift calculations with a 5 meter buffer zone. Long-term TER for use in fruit 
and both acute and long-term TER for use in vegetables pass the EU trigger based on Step 2 
calculations. 
3.3.4.3 Sediment dwelling organisms 
Spirotetramat is acutely toxic (48h EC50: 1.30 mg a.s./L) and showed moderate chronic 
toxicity (28d NOEC: 0.1 mg a.s./L (spiked water)) to chironomid larvae. Spirotetramat-enol, 
spirotetramat-ketohydroxy, 4-methoxycyclohexanone and spirotetramat-cis-metoxy-
cyclohexylamino carboxylic acid showed low to moderate acute toxicity (96h LC50: 75- >100 
mg/L) to chironomid larvae. Movento 100 SC is acutely toxic to chironomid larvae (48h 
EC50: 8.63 mg/L). 
Long-term TER for use in fruit fail the EU trigger based on Step 2 calculations, but pass the 
trigger based on drift calculations with a 5 meter buffer zone. Acute TER for use in fruit and 
both acute and long-term TER for use in vegetables pass the EU trigger based on Step 2 
calculations. 
3.3.4.4 Aquatic plants 
Spirotetramat and spirotetramat-enol are toxic to duckweed (14d EC50: 4.6-5.4 mg a.s./L). 
TER calculations for spirotetramat pass the EU triggers based on Step 2 calculations. 
3.3.4.5 Algae 
Spirotetramat showed very high toxicity to algae (72-96h EC50: 0.36-15 mg a.s./L). 
Spirotetramat-enol and 4-methoxycyclohexanone showed low toxicity (72h EC50: >100 
mg/L) to algae. Movento 100 SC showed low toxicity to algae (72h EC50: 134 mg/L). 
TER calculations for spirotetramat pass the EU triggers based on Step 2 calculations. 
3.3.4.6 Microorganisms 
Spirotetramat showed low acute toxicity to wastewater microorganisms in activated sludge 
(3h EC50 >10 000 mg a.s./L). 
3.3.4.7 Microcosm/Mesocosm studies 
No information. 
3.3.4.8 Bioconcentration 
No studies required for spirotetramat or the metabolites, since they all have log Pow below 
the trigger of 3. 
 
3.4 DOSSIER QUALITY AND COMPLETENESS 
The dossier is complete and is adequate as a basis for an evaluation of the active substance, 
metabolites and product. 
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4 Risk characterization 
4.1 SUMMARY OF HUMAN TOXICITY/INHERENT PROPERTIES  
In the terms of reference VKM was requested to consider possible health risk for operators 
related to the properties of the active substance spirotetramat and the product Movento 100 
SC ; in particular the relevance of the effects of spirotetramat on thyroid hormones, brain, 
thymus and body weight observed in dogs, and the reproductive effects of spirotetramat 
observed in rats.  
 
4.1.1 EFFECTS SEEN IN DOG STUDIES 
VKM discussed the seriousness of the effects in studies with dogs and concluded that thyroid 
and thymus glands are target organs in the oral subchronic toxicity studies, and that effects 
could be observed from 19 mg/kg bw/day (600 ppm). Decreases in circulating thyroid 
hormone levels were detected in three studies, and should be considered as toxicologically 
relevant. Furthermore, it cannot be excluded that the observed brain dilatation could be 
treatment-related. Higher doses of spirotetramat also induced decreased body weights.  
Thyroid and thyroid hormones: A dose–related decrease in thyroid hormones (T4 and T3) 
were observed in three different studies with spirotetramat, 28-days, 90-days and 1-year, both 
in male and female dogs. The hormonal decreases were significant from 400 ppm, 150 ppm 
and 200 (600) ppm, respectively, in the three studies. The T4 and T3 levels were measured at 
various time-points during the studies, and the onset for significant reduction of T4 and/or T3 
varied. The declines in circulating thyroid hormones were observed at lower concentrations 
than those needed for induced changes in thyroid weight and thyroid histopathology. Reduced 
thyroid follicular size was noted in two dogs at 1800 ppm (equal to 55 mg/kg bw/day). Thus, 
it cannot be excluded that the observed decline in thyroid hormones could be an early event in 
the development of hypothyroidism, and should therefore be considered as toxicologically 
relevant.     
Brain: Brain dilatation was observed in the 1-year study, and describes a condition where a 
brain ventricle is identified to be larger than expected. Dilated brain was observed in males at 
600 (mild) and 1800 ppm (moderate), and was noted in females, but only at 600 ppm 
(moderate); mild axonal degeneration was also detected in one female dog at 1800 ppm. The 
notifier (BCS) claimed that with a persistent incidence of only one individual dog per dose 
group (spirotetramat study and historical controls) and since brain ventricle dilation also has 
been observed in other BCS dog studies, there should be valid reasons to conclude that the 
phenomenon represents a pre-existing condition, and thus not treatment-related. VKM 
concludes, however, that although brain ventricle dilation has been observed in other dog 
studies, it cannot be excluded that this serious response could be treatment-related.  
Thymus and body weight: In addition to the thyroid, also the thymus gland is a target organ 
for spirotetramat in oral subchronic toxicity studies in dogs. Thymus involution was graded 
mild in one male at 600 ppm and moderate in one male at 1800 ppm. The thymus changes 
(decreased size and weight, atrophy and involution) were observed at high concentrations 
(600-6400 ppm) in all three dog studies (28-, 90- and 365 days). The effects on thymus should 
be considered toxicologically relevant. 
In the subchronic toxicity studies (28 and 90-days), a decrease in body weight, body weight 
gain, and food consumption was observed at the highest treatment doses (from 2,500 ppm and 
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higher). In the 1-year study there were no compound-related effects on body weights, even at 
the highest concentration (1800 ppm). Thus, doses of 2,500 ppm spirotetramat and higher 
seem to affect the dog body weight.  
 
4.1.2 THE EFFECTS SEEN IN RAT STUDIES  
Reproductive effects: In addition to testicular histopathology observed following subchronic 
and chronic exposure of male rats to spirotetramat, evidence of male reproductive toxicity 
was provided in the 2-generation reproductive toxicity study. Abnormal sperm cells were 
reported in F1-generation male rats treated with 6000 ppm (419 mg/kg bw/day) spirotetramat 
in the diet, and decreased reproductive performance was also observed in one of these males. 
The findings were supported by a 1-generation range-finding study. Renal toxicity was 
observed in the F1-adults in the 2-, but not the 1-generation study, and offspring toxicity was 
observed to be limited to reduced body weights. 
 In an investigative study designed to explore the time of onset of testicular toxicity in rats, 
decreased epididymal sperm counts were recorded after more than 10 days treatment to 1000 
mg/kg bw/day by gavage. Repeated dosing, therefore, seems necessary to produce male 
reproductive toxicity in rats. In a second investigative study of a spirotetramat metabolite, 
male rats were treated by gavage with the enol metabolite (formed by enzymatic cleavage of 
parent compound) for 21 days at a dose of 800 mg/kg bw/day. Spermatotoxicity, abnormal 
sperm, and Sertoli cell vacuolation were observed in the testis-epididymides of treated 
animals. Therefore, male reproductive toxicity in rats is likely due to the enol metabolite (or 
further oxidation products) of spirotetramat. The testicular toxicity was not observed in mice, 
probably due to the high conjugation of the enol metabolite with glucuronic acid 
(approximately 30%). The notifier claimed that based on a metabolic similarity between mice 
and humans, it is likely that humans are also less sensitive to the enol metabolite toxicity than 
rats. However, VKM concludes that due to the low conjugation in human liver cells at high 
doses (only 2%), as well as the far lower conjugation in humans compared to mice, it cannot 
be assumed that humans are fundamentally different from rats with regard to sensitivity to 
spirotetramat. Thus, VKM concludes that the reproductive effect in rats could be relevant for 
humans. 
 
Neurotoxicity: Clinical signs of toxicity and decreased motor activity were observed 
following one single dose of 200 mg/kg bw spirotetramat to rats.    
 
4.1.3 ESTABLISHMENT OF REFERENCE VALUES  
NOAEL 
VKM concludes on a NOAEL of 5 mg/kg bw/day (200 ppm) for spirotetramat based on 1- 
year toxicity study in dogs,  and is of the opinion that the test substance-related decrease in 
thyroid hormone levels, thymus involution and brain dilation is relevant for humans.  
Furthermore, a NOAEL of 100 mg/kg bw/day based on the acute neurotoxicity study in rats is 
used to establish the ARfD value. 
ADI  
An ADI of 0.05 mg/kg bw/day is proposed for spirotetramat based on applying a 100-fold 
uncertainty factor on the NOAEL of 5 mg /kg bw/day in the 1- year toxicity study in dogs. 
The uncertainty factor accounts for interspecies extrapolation (10X) and intraspecies 
variability (10X).  
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AOEL 
An AOEL of 0.05 mg/kg bw/day is proposed for spirotetramat based on the NOAEL of 5 mg 
/kg bw/day determined in the 1- year toxicity study in dogs.  
ARfD  
An ARfD of 1 mg/kg bw/day is proposed for spirotetramat based on NOAEL of 100 mg/kg 
bw/day in the acute neurotoxicity study in rats.  
 
4.2 HEALTH RISK CHARACTERIZATION 
4.2.1 HEALTH RISK DUE TO HUMAN EXPOSURE 
VKM has based the risk characterization for operators on the summary from the Norwegian 
Food Safety Authority (section 5.5), and related this to the suggested AOEL value as 
indicated here in section 2.1. 
4.2.1.1 Operator, worker and bystander exposure 
Operator exposure: 
The AOEL for spirotetramat is not exceeded when applied in greenhouses, even if no 
personal protective equipment (PPE) is used.  On fruit trees in field there is a medium excess 
of AOEL without PPE, but no excess with PPE (Gloves during mixing and loading, and 
gloves, coveralls and sturdy footwear during application).  
Worker and bystander exposure: 
The AOEL is slightly exceeded for fruit trees, and thus the use of gloves is recommended. 
4.2.2 HEALTH RISK DUE TO RESIDUES IN PRODUCTS FOR CONSUMPTION 
Not included in the terms of reference. 
 
4.3 ENVIRONMENTAL FATE ASSESSMENT 
VKM was also asked to consider the fate and behaviour of Movento 100 SC and the active 
ingredient spirotetramat in the environment, and the ecotoxicological effects and risks related. 
4.3.1 DEGRADATION IN SOIL  
Spirotetramat degrades very quickly to spirotetramat-enol in soil (DT50: 0.1 – 0.3 days). The 
relevant metabolites are also degraded at high to medium rates. Spirotetramat and its 
metabolites are not expected to accumulate in soil.  
4.3.2 MOBILITY IN SOIL AND LEACHING TO GROUNDWATER 
Sorption studies indicate medium sorption of spirotetramat to soil and moderate to low 
sorption of the main metabolites. Due to the rapid degradation in soil, no significant leaching 
of spirotetramat to groundwater is expected. Leaching models show concentrations of relevant 
metabolites below 0.001 µg/L for all FOCUS scenarios. Hence, VKM considers it unlikely 
that spirotetramat or any of its metabolites will reach concentrations above the threshold level 
of 0.1 μg/L when the formulation Movento 100 SC is applied according to the intended use. 
4.3.3 SURFACE WATER CONCENTRATIONS 
Surface water concentrations of spirotetramat and the relevant metabolites have been 
calculated using FOCUS models, step 2. Additional calculations were performed including a 
5 m buffer zone. VKM considers the calculated maximum PEC values as shown in section 
3.3.2 to be relevant for aquatic risk assessment.  
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4.4 ENVIRONMENTAL RISK CHARACTERIZATION 
The risk characterization of the product’s ecotoxicological effects on terrestrial and aquatic 
organisms made by VKM is based on the summary from the Norwegian Food Safety 
Authority presented in section 3.3 and using the risk scale described in section 2.2. 
4.4.1 EFFECTS AND RISKS TO TERRESTRIAL ORGANISMS 
VKM concludes that the risk for toxic effects of spirotetramat to mammals, birds, 
earthworms, and soil microorganisms is minimal with the proposed application regime. 
Extended laboratory studies with non-target arthropods Movento 100 SC showed effects 
above the trigger of  50% mortality for one species of predatory mites (T. pyri) at and above 
application doses of 42 g/ha, while the proposed application rate is 225 g/ha. Although a field 
study did not show any effects on the mite fauna, VKM considers that in-field effects on 
sensitive species of predatory mites in the fields cannot be excluded.  
The acute contact and oral toxicity of spirotetramat to adult bees is low. Transient effects on 
honey-bee brood were observed under worst-case scenarios in some semi-field studies. 
However, no adverse effects were observed in field studies and VKM concludes that the risk 
of adverse effects on bees is minimal providing that spirotetramat is not used on crops during 
flowering or when bees are actively foraging. 
4.4.2 EFFECTS AND RISK TO AQUATIC ORGANISMS  
VKM concludes that there is a minimal risk for toxic effects of spirotetramat to fish, aquatic 
plants, and algae with the proposed application regime. For invertebrates and sediment 
dwelling organisms, minimal risks are calculated provided that a 5 m buffer zone is used. 
 
4.5 QUALITY OF THE SUBMITTED DOCUMENTATION 
VKM is of the opinion that the documentation submitted to VKM is adequate as a basis for an 
evaluation of the active substance, the metabolites, and for the technical material.  
 
5 Conclusion 
5.1 HEALTH 
VKM concludes that spirotetramat show toxic effects in dogs and rats that could be relevant 
for humans. Thyroid and thymus glands are target organs in the oral subchronic toxicity 
studies in dogs. Decreases in circulating thyroid hormone levels were detected in all three 
studies carried out with dogs (28-, 90-days and 1-year) and should be considered 
toxicologically relevant. It cannot be excluded that the brain dilatation observed in the 1-year 
dog study is treatment-related.  
Furthermore, VKM concludes that the reproductive effect observed in rats should be 
considered relevant for humans. 
VKM proposes a NOAEL of 5 mg/kg bw/day for spirotetramat based on a 1- year toxicity 
study in dogs, and a NOAEL of 100 mg/kg bw/day based on the acute neurotoxicity study in 
rats. 
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VKM proposes: 
• ADI: 0.05 mg/kg bw/day. 
• AOEL: 0.05 mg/kg bw/day. 
• ARfD: 1 mg/kg bw/day. 
 
Risk calculations show minimal risk if personal protective equipment is used. 
 
5.2 ENVIRONMENT 
VKM concludes that spirotetramat and its metabolites are not expected to accumulate in soil. 
It is not expected that spirotetramat or any of its metabolites will reach concentrations in 
groundwater above the threshold level of 0.1 μg/L when the formulation Movento 100 SC is 
applied according to the intended use. 
VKM concludes that use of Movento 100 SC with the active substance spirotetramat 
according to the proposed application scheme in Norway represents a minimal risk of adverse 
effects on terrestrial mammals, birds, earthworms, and soil microorganisms. However, in-
field effects on sensitive species of predatory mites in the crop cannot be excluded. 
The risk of adverse effects on bees is minimal providing that spirotetramat is not used on 
crops during flowering or when bees are actively foraging. 
For aquatic organisms in surface water, the risk is considered minimal, provided that a 5 m 
buffer zone to open water is used. 
 
6 Documentation 
The documentation submitted by the applicant in the process of application for registration of 
Movento 100 SC has been compiled and evaluated by The Norwegian Food Safety Authority 
(www.Mattilsynet.no). 
In addition, VKM has performed a combined literature search in PubMed, TOXNET and 
Embase using the name of the active substance (spirotetramat). The resulting references has 
been considered by VKM and used in the risk assessment when relevant. 
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